BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has maintained a 'Market Perform' rating on Fate Therapeutics (NASDAQ:FATE) and raised the price target from $5.4 to $6.

November 09, 2023 | 7:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fate Therapeutics' price target has been raised from $5.4 to $6 by BMO Capital, with a maintained 'Market Perform' rating.
The raised price target indicates that the analyst sees potential for the stock's price to increase. This could lead to positive sentiment among investors, potentially driving the stock price up in the short term. However, the 'Market Perform' rating suggests that the stock is expected to perform similarly to the overall market, indicating a neutral outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100